According to this press release by GlaxoSmithKline (GSK) Pharmaceuticals, a drug formulation for a childrens' medication for HIV received a New Drug Application (NDA) approval on March 30th, of 2022.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv/

Also, according to this press release, ViiV Healthcare, Pfizer, and Shionogi were cooperating partners. Additionally, ViiV Healthcare works directly with the "Clinton Health Access Initiative (CHAI) and Unitaid."

It makes sense, as CHAI is dedicated to "strengthening health systems around the world and expanding access to care and treatment of HIV/AIDS, malaria, and other illnesses."

But guess who sits on the board of the CHAI? Our good friends Chelsea and Bill!

https://www.clintonhealthaccess.org/about-us/#board

Interesting that the Pharma world is gearing up for the treatment of HIV in children, isn't it? And this drug combo has no causal mechanism linking heart attacks and its usage, so the "evidence... is inconclusive."

https://www.fda.gov/drugs/types-applications/new-drug-application-nda

Edit: Corrected typo. Changed "words" to "works."